PMIS Therapeutic
Cancer
Key Facts
About NaturemiRI
NaturemiRI is an early-stage biotech leveraging its patent-pending Plasmid-based MicroRNA Inhibitor System (PMIS) to target miRNA biology. The platform enables the generation of transgenic animal models and stable cell lines for research and has advanced into therapeutic development for indications like cancer, tissue regeneration, and arthritis. Operating from Cambridge, the company appears to be privately held and pre-revenue, focusing on both research product sales and therapeutic pipeline advancement.
View full company profileAbout NaturemiRI
NaturemiRI is an early-stage biotech leveraging its patent-pending Plasmid-based MicroRNA Inhibitor System (PMIS) to target miRNA biology. The platform enables the generation of transgenic animal models and stable cell lines for research and has advanced into therapeutic development for indications like cancer, tissue regeneration, and arthritis. Operating from Cambridge, the company appears to be privately held and pre-revenue, focusing on both research product sales and therapeutic pipeline advancement.
View full company profileAbout NaturemiRI
NaturemiRI is an early-stage biotech leveraging its patent-pending Plasmid-based MicroRNA Inhibitor System (PMIS) to target miRNA biology. The platform enables the generation of transgenic animal models and stable cell lines for research and has advanced into therapeutic development for indications like cancer, tissue regeneration, and arthritis. Operating from Cambridge, the company appears to be privately held and pre-revenue, focusing on both research product sales and therapeutic pipeline advancement.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |
| Undisclosed DDR Sensor Program(s) | NERx Biosciences | Pre-clinical |